Analyst Ratings For Alpine Immune Sciences (NASDAQ:ALPN)
Today, Ladenburg Thalmann Financial Services initiated coverage on Alpine Immune Sciences (NASDAQ:ALPN) with a Buy with a price target of $17.00.
There are 4 hold ratings, 3 buy ratings on the stock.
The current consensus rating on Alpine Immune Sciences (NASDAQ:ALPN) is Hold (Score: 2.43) with a consensus target price of $10.88 per share, a potential 27.26% upside.
Some recent analyst ratings include
- 7/27/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
- 4/19/2017-Cowen and Company Reiterated Rating of Hold.
- 11/29/2016-HC Wainwright Reiterated Rating of Buy.
- 11/29/2016-Raymond James Financial, Inc. was Downgraded by analysts at Raymond James Financial, Inc. from a “Outperform ” rating to a ” Market Perform” rating.
- 11/29/2016-Robert W. Baird was Downgraded by analysts at Robert W. Baird from a “Outperform ” rating to a ” Neutral” rating. They now have a $3.00 price target on the stock, up previously from $29.00 .
- 11/29/2016-Stifel Nicolaus was Downgraded by analysts at Stifel Nicolaus from a “Buy ” rating to a ” Hold” rating. They now have a $3.25 price target on the stock, up previously from $16.00 .
- 8/30/2016-Piper Jaffray Companies Reiterated Rating of Buy.
Recent Insider Trading Activity For Alpine Immune Sciences (NASDAQ:ALPN)
Alpine Immune Sciences (NASDAQ:ALPN) has insider ownership of 3.00% and institutional ownership of 52.96%.
- On 6/20/2017 Value Fund L P Biotechnology, Insider, bought 17,806 with an average share price of $2.25 per share and the total transaction amounting to $40,063.50. View SEC Filing
- On 6/7/2017 Bvf Partners L P/Il, Major Shareholder, bought 36,900 with an average share price of $2.28 per share and the total transaction amounting to $84,132.00. View SEC Filing
- On 6/7/2017 Value Fund L P Biotechnology, Insider, bought 72,650 with an average share price of $2.29 per share and the total transaction amounting to $166,368.50. View SEC Filing
- On 6/5/2017 Bvf Partners L P/Il, Major Shareholder, bought 35,750 with an average share price of $2.29 per share and the total transaction amounting to $81,867.50. View SEC Filing
- On 5/31/2017 Value Fund L P Biotechnology, Insider, bought 47,000 with an average share price of $2.27 per share and the total transaction amounting to $106,690.00. View SEC Filing
- On 5/19/2017 Value Fund L P Biotechnology, Insider, bought 78,858 with an average share price of $2.30 per share and the total transaction amounting to $181,373.40. View SEC Filing
- On 5/11/2017 Value Fund L P Biotechnology, Insider, bought 109,034 with an average share price of $2.32 per share and the total transaction amounting to $252,958.88. View SEC Filing
Recent Trading Activity for Alpine Immune Sciences (NASDAQ:ALPN)
Shares of Alpine Immune Sciences closed the previous trading session at 8.55 down -0.23 -2.67% with 11,027 shares trading hands.